Navigation Links
Alleged NuvaRing Blood-Clotting Lawsuits Update: Resource4thePeople Reports Important Hearing Scheduled for July
Date:5/26/2013

San Diego, CA (PRWEB) May 26, 2013

http://www.resource4thepeople.com/defectivedrugs/nuvaring.html

Resource4thePeople announced today it is informing consumers about an important hearing scheduled in consolidated federal NuvaRing lawsuits alleging that women who used the popular contraceptive suffered serious blood-clotting side effects.

The judge overseeing the lawsuits has scheduled a status hearing for June 21, 2013 at which lawyers for the plaintiffs alleging these side effects and NuvaRing defense attorneys will inform the judge about the progress of more than 1,090 lawsuits involved in the litigation, according to the court file.*

“Among the items to be discussed at this hearing, according to the court docket, is the disposition of the six trial pool cases that have been selected by the judge,” said Resource4thePeople.

“The agenda shows that the judge is moving forward toward resolving these cases. As he does we are answering inquiries from consumer about their eligibility to join in this litigation or file their own actions elsewhere and want to assure them that our national network of attorneys is continuing to accept cases involving alleged NuvaRing blood-clotting side effects.”

The cases that have been consolidated before U.S. District Judge Rodney Sippel involve common allegations that are summed up on the court’s multidistrict litigation web site and include the following language:

“NuvaRing is a prescription contraceptive device used by women throughout the United States. The individual plaintiffs in this matter claim that use of NuvaRing caused them injuries. They have filed suit in several state and federal courts alleging that the manufacturer of NuvaRing failed to adequately warn of the risks associated with the use of the product, and/or that the NuvaRing product is otherwise defective and unreasonably dangerous.” **

The information on the web site was posted after the Judicial Panel on Multidistrict Litigation consolidated the NuvaRing cases on August 22, 2008, and transferred the cases to Judge Sippel to conduct pretrial evidence-gathering for all of the cases.

The first bellwether trial from a pool of federal lawsuits involving claims that the NuvaRing puts women at higher risk of suffering blood clots than other contraceptives has been scheduled to begin in October.

Meanwhile, more NuvaRing lawsuits involving similar allegations are being filed, and one of the most recent*** was filed by a Philadelphia woman who claims she suffered a venous sinus thrombosis and an intracranial hemorrhage last year.

In her lawsuit, the woman is claiming that those problems were caused by blood clotting caused by her use of a NuvaRing IUD over seven years. In her court filing, the woman said she has been forced to undergo a daily Coumadin regimen for her health problems, and suffers from depression and social anxiety.

Named as defendants are Organon Pharmaceuticals USA Inc., Organon International Inc. and Schering-Plough Corp., who, according to the court file, allegedly falsely marketed and sold the NuvaRing as a safe, efficient alternative to birth control pills.

As with the NuvaRing lawsuits in the multidistrict litigation, the Philadelphia woman claims that the defendants were negligent in not fully informing the public and health care professionals about increased risk of blood-clotting from the use of the contraceptive, according to the court filing.

The allegations cited in the multidistrict litigation claim that the NuvaRing, described by company officials as the first hormonal IUD, puts women at risk of suffering blood clots that can lead to life-threatening health problems because of the hormone mixture that prevents pregnancies.

The NuvaRing was approved by the Food and Drug Administration in 2001 after being created by Organon as a flexible IUD, or ring, hence the name. The IUD releases a low dose of etonogestrel and estrogen over three weeks, providing women the flexibility of a monthly contraceptive.

This flexibility was one of the marketing factors that made the NuvaRing what was described as an easy and healthy contraceptive choice to women who were not satisfied with the side effects caused by birth control pills and the necessity of taking them each day.

However, on Oct. 27, 2011 the FDA released the findings of government research that put women who used the NuvaRing or other IUDs with a similar mixture of hormones at a 56 percent higher risk of suffering blood clotting that led to deep vein thrombosis and pulmonary embolisms than women on birth control pills.****

Resource4thePeople also notes that NuvaRing has now posted warnings about the increased risks of suffering blood clots on the company’s web site under the heading of “IMPORTANT SAFETY INFORMATION.*****

"Our legal consultations can spell out the options available to women who may have suffered health problems from blood clotting, such as deep vein thrombosis, pulmonary embolisms, strokes and heart attacks," said Resource4thePeople.

Sources:

  • In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, U.S. District Court, Eastern District of Missouri
** http://www.moed.uscourts.gov/node/117
*** Case No. 2:13cv0099, U.S. District Court for the Eastern District of Pennsylvania
****http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf FDA Oct. 27, 2011
***** http://www.nuvaring.com/Consumer/index.asp

Read the full story at http://www.prweb.com/releases/2013/5/prweb10766846.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases
2. Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes
3. Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications
4. 2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning
5. Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications
6. 2013 Alleged Transvaginal Mesh Complications Lawsuits Update: Resource4thePeople Reports Defendants Ordered to Provide Testimony, Documents
7. Injury Law Firm Announces New Informative Graphic on Common Medicines That Have Allegedly Been Linked to Stevens Johnson Syndrome
8. Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups
9. Alleged Zoloft Birth Defects Lawsuits Report from Resource4thePeople: Federal Judge Schedules Important Status Conference
10. Mississippi Woman’s Injuries Allegedly Caused by Ethicon Inc.’s Transvaginal Mesh Device; Parker Waichman LLP Files Lawsuit
11. Alleged Bard IVC Filter Failure Lawsuits Update: Resource4thePeople Reports New Cases Continue To Be Filed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 2017 , ... The 89th Academy Awards will be celebrated this weekend, which ... Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” to ... the Center for American Progress (CAP), for its report, Lessons From State Performance on ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which is ... in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) ... website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients and ...
(Date:2/23/2017)... ... 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will ... to Hot,” which will begin airing on February 24, 2017. The show chronicles the ... 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
(Date:2/23/2017)... Angeles, California (PRWEB) , ... February 23, 2017 ... ... Global Sports Development will host a diverse symposium on “Doping in ... of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb 24, 2017 Research and ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... drug pricing data and benchmarks in the global Urinary Incontinence market. ... What are the key drugs marketed for Urinary Incontinence and ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
(Date:2/23/2017)... , Südkorea, 23. Februar 2017 LG Innotek ... Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls ... Strahlung im Bereich zwischen 200 und 280 nm und eignet ... Bakterien, indem es ihre DNA zerstört. Das Produkt von ... ...
Breaking Medicine Technology: